Work productivity during allergy season: the role of antihistamine choice | Ukrainian Medical Journal

Allergic rhinitis affects not only the patient’s well-being, but also sleep, concentration, academic and work productivity. This is of particular importance for people whose activities require prolonged concentration, quick reaction or work with complex equipment. The article considers three typical clinical situations: a drone operator, a public transport driver and a student during the exam period. It is shown that when choosing antihistamine therapy, it is necessary to take into account not only the effectiveness of symptom control, but also the sedative potential of the drug and its effect on psychomotor functions. Bilastine — a 2nd-generation H₁-antihistamine drug — demonstrated comparable efficacy to cetirizine in allergic rhinitis, a favorable tolerability profile and did not impair driving performance.

References

1. Brożek J.L., Bousquet J., Agache I. et al. (2017) Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines — 2016 revision. J. Allergy Clin. Immunol., 140(4): 950–958. doi.org/10.1016/j.jaci.2017.03.050.
2. Szeinbach S.L., Seoane-Vazquez E.C., Beyer A. et al. (2007) The impact of allergic rhinitis on work productivity. Primary Care Respiratory J., 16(2): 98–105. doi.org/10.3132/pcrj.2007.00015.
3. Vandenplas O., Vinnikov D., Blanc P.D. et al. (2018) Impact of rhinitis on work productivity: A systematic review. J. Allergy Clin. Immunol.: In Practice, 6(4): 1274–1286.e9. doi.org/10.1016/j.jaip.2017.09.002.
4. Katelaris C.H., Lai C.K.W., Rhee C.S. et al. (2011) Nasal allergies in the Asian-Pacific population: Results from the Allergies in Asia-Pacific Survey. Am. J. Rhinol. Allergy, 25(Suppl. 1): S3–S15. doi.org/10.2500/ajra.2011.25.3674.
5. Dykewicz M.S., Wallace D.V., Amrol D.J. et al. (2020) Rhinitis 2020: A practice parameter update. J. Allergy Clin. Immunol., 146(4): 721–767. doi.org/10.1016/j.jaci.2020.07.007.
6. Chantaphakul H., Chiewchalermsri C., Mairiang D. et al. (2025) Allergic rhinitis and urticaria burden and antihistamine treatment options in Thailand: A modified Delphi study. Journal of Allergy and Clinical Immunology: Global, 4(2): Article 100444. doi.org/10.1016/j.jacig.2025.100444.
7. Canonica G.W., Kuna P., Maurer M. et al. (2024) Bilastine for the treatment of allergic rhinoconjunctivitis and urticaria: Results from an international Delphi study. Drugs in Context, 13: 2024-2-3. doi.org/10.7573/dic.2024-2-3.
8. Vieira R.J., Sousa-Pinto B., Bousquet J. et al. (2026) Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI guidelines–2024–2025 revision: Part II–Guidelines on oral and ocular treatments. Allergy. Advance online publication. doi.org/10.1111/all.70305.
9. Kuna P., Bachert C., Nowacki Z. et al. (2009) Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: A randomized, double-blind, parallel-group study. Clin. Experiment. Allergy, 39(9): 1338–1347. doi.org/10.1111/j.1365-2222.2009.03257.x.
10. Pawar S.P., Gosavi P.A., Kalikar M.V. (2025) A comparative study of efficacy and tolerability of cetirizine and bilastine in patients of allergic rhinitis: An open-label, randomized, parallel-group study. Perspectives in Clin. Res., 16(4): 191–197. doi.org/10.4103/picr.picr_164_24.
11. Conen S., Theunissen E.L., Van Oers A.C.M. et al. (2011) Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. Journal of Psychopharmacology, 25(11): 1517–1523. doi.org/10.1177/0269881110382467.
12. Demonte A., Guanti M.B., Liberati S. et al. (2018) Bilastine safety in drivers who need antihistamines: New evidence from high-speed simulator driving test on allergic patients. European Review for Medical and Pharmacological Sciences, 22(3): 820–828. doi.org/10.26355/eurrev_201802_14318.
13. Chakraborty S.S., Podder I., Das M. et al. (2026) Effectiveness, safety, and tolerability of bilastine up-dosing in chronic spontaneous urticaria uncontrolled with licensed doses of other second-generation antihistamines–An institution-based, open-label, single-group longitudinal trial. Indian Dermatol. Online J., 17(2): 220–224. doi.org/10.4103/idoj.idoj_7_25.
14. Ніксар: інструкція для медичного застосування лікарського засобу. compendium.com.ua/dec/264776.